Joseph P. Lyssikatos
CHIEF SCIENTIFIC OFFICER at Enliven Therapeutics. Based in Boulder, Colorado.
- Rank
- 1765th of 14,452
- Companies held
- 1
- Largest holding
- ELVN, 100.0% of total
- Latest SEC filing
- Feb 12, 2026
What the $81.3M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Enliven Therapeutics ELVN Common Stock | Indirectly (see filing footnote) | 992,658 | $46.41 | $46.1M | 56.7% | Form 4, May 1, 2025 |
| Enliven Therapeutics ELVN Common Stock | Through Lyssikatos Revocable Trust | 740,188 | $46.41 | $34.4M | 42.3% | Form 4, Feb 12, 2026 |
| Enliven Therapeutics ELVN Common Stock | Directly | 18,750 | $46.41 | $870K | 1.1% | Form 4, Feb 12, 2026 |
Share counts are the amounts Joseph P. Lyssikatos reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 6, 2026 | Sold | ELVN | 5,000 | $29.04 | $145K | View |
| Jan 20, 2026 | Sold | ELVN | 14,509 | $26.90 | $390K | View |
| Jan 20, 2026 | Sold | ELVN | 5,491 | $26.37 | $145K | View |
| Jan 9, 2026 | Sold | ELVN | 41,198 | $24.90 | $1.0M | View |
| Jan 9, 2026 | Sold | ELVN | 50,000 | $29.13 | $1.5M | View |
| Jan 8, 2026 | Sold | ELVN | 7,500 | $20.13 | $151K | View |
| Jan 8, 2026 | Sold | ELVN | 33,802 | $24.92 | $842K | View |
| Dec 19, 2025 | Sold | ELVN | 5,000 | $16.84 | $84K | View |
| Nov 19, 2025 | Sold | ELVN | 12,008 | $22.30 | $268K | View |
| Nov 19, 2025 | Sold | ELVN | 492 | $23.09 | $11K | View |
| Oct 20, 2025 | Sold | ELVN | 12,500 | $22.08 | $276K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 1762 | Shawn Henry CHIEF SECURITY OFFICER, CrowdStrike Holdings. New York, NY | $81.6M |
| 1763 | Nelson Knight President Real Estate & Invest, Apple Hospitality REIT. Richmond, VA | $81.5M |
| 1764 | Michael F. Mahoney Chairman, President & CEO, Boston Scientific. Marlborough, MA | $81.4M |
| 1765 | Joseph P. Lyssikatos CHIEF SCIENTIFIC OFFICER, Enliven Therapeutics. Boulder, CO | $81.3M |
| 1766 | Lloyd D. Frink Co -Exec. Chairman & President, Zillow Group. Seattle, WA | $81.3M |
| 1767 | Michael Eugene McBride Chief Revenue Officer, GitLab. Not Applicable, DE | $81.2M |
| 1768 | Scott Staples Chief Executive Officer, First Advantage. Atlanta, GA | $81.2M |
Other Enliven Therapeutics insiders
All ELVN insiders- Mark Chin$109MDirector. #1385 overall
- Samuel Kintz$41.3MPRESIDENT AND CEO. #2926 overall
- Anish Patel$10.9MCHIEF OPERATING OFFICER. #8208 overall
- Braden M Leonard$10.7M10% owner. #7717 overall
- David M. Mott$10.6MDirector. #4905 overall
- Richard A. Heyman$6.8MDirector. #9780 overall
Questions
How much stock does Joseph P. Lyssikatos own?
Joseph P. Lyssikatos holds $81,291,570 in listed stock based on SEC filings and current prices, mostly Enliven Therapeutics (ELVN). That ranks 1765th on the Stock Rich List.
Is this Joseph P. Lyssikatos's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Joseph P. Lyssikatos last buy or sell stock?
The most recent open-market trade on file is a sale of 5,000 ELVN shares on Feb 6, 2026 at $29.04.